Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX AMZN BIIB IBB TSLA ALXN WYNN AMGN GMCR COST SIAL AAPL Z VRTX MNST CELG SLXP WDC
Nyse: ACT V LNKD AGN IVV GS LMT SPG PXD FDX IBM MMM CMI APD GD TWC NOC HUM BA PH
New Highs: BLK V SHW PPG IVV WHR RL FDX BCR AMGN MMM FLT APD GD COST NOC PH AMP BDX FFIV

The Hot Industries

Medical Instruments & Supplies 2
Asset Management 2
Specialty Chemicals 2

The Hot Sectors

Industrial Goods 4
Healthcare 3
Financial 3

IBB Stock Chart

IBB

favicon

Weekly Wrap from Briefing.com

21 Nov 2014, 4:55 pmWeekly Wrap from Briefing.com
favicon

InPlay from Briefing.com

21 Nov 2014, 3:06 pmInPlay from Briefing.com
favicon

CB Pharma on deck for IPO

21 Nov 2014, 10:02 amCB Pharma Acquisition Corp. (CNLMU) files for an IPO of 4M units priced at $10 per unit.
favicon

ETF Preview: ETFs, Futures Lower on Weak Global Economic Data; Philly Manufacturing Data, Leading Econ Indicators ...

20 Nov 2014, 11:07 amETF Preview: ETFs, Futures Lower on Weak Global Economic Data; Philly Manufacturing Data, Leading Econ Indicators Still Ahead
favicon

S1 Biopharma set for IPO

14 Nov 2014, 11:31 amNew York, NY-base S1 Biopharma (Pending: SXB ) is set for its IPO of 2.75M shares of common stock at $12 - 14. The clinical stage biopharmaceutical firm develops therapies for sexual dysfunction.
favicon

1 Biotech Beast Worth Tracking

12 Nov 2014, 10:08 amWith the help of an almost vertical rise in the overall stock market, most industries within the market have also performed very well. As they say, “a rising tide raises all ships.” Some industries, however, ...
favicon

PRA Health Sciences on deck for IPO

11 Nov 2014, 12:17 pmThe contract research organization provides clinical development services (Phases 1 - 4) to the biotech and pharmaceutical industries. Since 2000, the company has performed ~2,300 clinical trials.
favicon

Amgen's stock drops after trial misses secondary endpoint

4 Nov 2014, 7:36 amNEW YORK (MarketWatch) -- Amgen Inc.'s stock dropped 1.6% in premarket trade Tuesday, after a late-stage study of the biotechnology company's treatment for ovarian cancer failed to meet its secondary endpoint. The Phase 3 trial, which evaluated trebananib plus paclitaxel versus a placebo, "did not demonstrate a statistically significant improvement in overall survival," Amgen said in a statement ...
favicon

Geron's stock soars after FDA lifts hold on new drug application

3 Nov 2014, 6:06 amNEW YORK (MarketWatch) -- Geron Corp.'s stock soared 35% in premarket trade Monday, after the company said the Food and Drug Administration lifted its hold on the investigational new drug application for its cancer treatment imetelstat. Geron added that the FDA also accepted its development plan for imetelstat. The company now expects to start a Phase 2 clinical trial of imetelstat focused on ...
favicon

Best And Worst ETFs Of The Week Amid Biotech Breakout

24 Oct 2014, 2:41 pmThe stock market added to gains this week as the V-shaped rebound in equities continued to lure buyers into catching a month-end rally. The SPDR S&P 500 ETF (NYSE: SPY ) gained 4 percent during the week ...